MENU
JANX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Janux Therapeutics (JANX) Ownership - Who owns Janux Therapeutics?
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer... Show more
Profile
Industry
N/A
Address
10955 Vista Sorrento Parkway
Phone
+1 858 751-4493
Employees
64
Web
https://www.januxrx.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
1.38B
P/E Ratio
N/A
Total Cash
996.01M
Projected Growth
N/A
Total Debt
22.19M
Revenue
439K
Risk (Beta)
3.29
Dividend Yield
N/A
Total Cash/Share
16.57
Total Debt/Equity
N/A
Revenue/Share
0.01 USD as % of share price
Fundamentals
JANX
Capitalization
1.39B
P/E Ratio
N/A
Risk (Beta)
3.29
Dividend Yield
N/A
Total Cash
996M
Total Cash/Share
16.57
Total Debt
22.2M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.01%
Revenue
439K
ROE
N/A
Book Value
991M
P/B Ratio
1.40
Cash Flow
N/A
Earnings
-1.81
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
59K
Current Ratio
47.03
Current Revenue Per Employee
5776.32
Dividends Per Share - Security
N/A
EBITDA
-142.8M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-12.26
Shares Held By Institutions
2.68B
Shares Outstanding - Current
60.1M
Total Liabilities
41.7M
Total Volume MTD
N/A
Value
-1
Gain YTD
-56.967
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. JANX showed earnings on August 07, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
10955 Vista Sorrento Parkway
Phone
+1 858 751-4493
Employees
64
Web
https://www.januxrx.com